PLUS1
Best deals to access real time data! |
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 146.32 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Sage Therapeutics Inc | SAGE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 5.53 | 3.93% | 146.32 | 146.94 | 140.645 | 142.05 | 140.79 | 19:59:41 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 138.75 | 148.00 | 9.25 | 6.25% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,016 | 302,685 | $ 144.44 | $ 43,718,971 | 367,544 | 79.88 - 193.56 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:00:56 | 2 | $ 146.99 | USD |
Sage Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 7.56B | 51.66M | $ -372.88M | -8.07 | - | 50.80M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 3.00 | 1.70% |
Sage Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/12/2019 | 07:18 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 11/12/2019 | 06:45 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/12/2019 | 06:31 | Business Wire | Sage Therapeutics Announces Third Quarter 2019 Financial.. |
| 11/11/2019 | 16:30 | Business Wire | Sage Therapeutics to Present at the Stifel 2019 Healthcare.. |
| 11/05/2019 | 18:00 | Business Wire | Sage Therapeutics Announces Inducement Grants Under NASDAQ.. |
| 10/09/2019 | 06:30 | Business Wire | Sage Therapeutics to Report Third Quarter 2019 Financial.. |
| 10/02/2019 | 16:30 | Business Wire | Sage Therapeutics Announces Inducement Grants Under NASDAQ.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SAGE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 138.89 | 154.32 | 136.52 | 143.23 | 369,004 | 7.43 | 5.35% |
| 1 Month | 144.01 | 154.32 | 134.16 | 141.80 | 356,160 | 2.31 | 1.6% |
| 3 Months | 169.45 | 173.755 | 134.15 | 148.67 | 372,478 | -23.13 | -13.65% |
| 6 Months | 165.07 | 193.56 | 134.15 | 161.74 | 372,629 | -18.75 | -11.36% |
| 1 Year | 107.10 | 193.56 | 79.88 | 148.89 | 456,236 | 39.22 | 36.62% |
| 3 Years | 54.03 | 195.97 | 44.55 | 122.56 | 510,555 | 92.29 | 170.81% |
| 5 Years | 35.49 | 195.97 | 26.2801 | 94.33 | 481,529 | 110.83 | 312.29% |
Sage Therapeutics Description
| Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development. |
